期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 244, 期 1-2, 页码 133-136出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2006.01.012
关键词
optic neuritis; adalimumab; humira; etanercept; enbrel; infliximab; remicade; tumor necrosis factor
We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of antitumor necrosis factor-alpha (TNF-alpha) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events. (c) 2006 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据